New safety study monitors liver risks in kids taking livmarli
NCT ID NCT07293897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is monitoring 50 children in Japan with Alagille syndrome (ALGS) or progressive familial intrahepatic cholestasis (PFIC) who are taking the drug Livmarli (maralixibat). Researchers are using a national registry to track how many children develop liver problems and how quickly they appear. The goal is to better understand the safety of Livmarli in these rare liver conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Maralixibat (Livmarli oral solution)
- What this could lead to
- If successful, this study will provide real-world safety data on liver risks for children with ALGS or PFIC taking Livmarli, helping doctors make informed treatment decisions.
- What could go wrong
- This is an observational registry study, not a controlled trial, so it cannot prove cause and effect. The small sample size (50 patients) may limit how widely the results apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALAGILLE SYNDROME (ALGS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.